Alzheimer's disease (AD) is associated with a striking reduction in the activity of the α-ketoglutarate dehydrogenase complex (KGDHC). The deficiency occurs in brains from AD patients of undefined etiology, and in fibroblasts from both sporadic and familial AD cases. To further assess the nature of the abnormality of KGDHC in AD, KGDHC activities and immunoreactivities were analyzed in brains from AD patients bearing the Swedish APP670/671 mutation. This gene defect causes overproduction of the amyloid β peptide. KGDHC activities were reduced by 55 to 57% compared with control values in the mutation-bearing AD cases in the medial temporal and superior frontal cortices. The immunochemical levels of KGDHC subunits Elk (- 51%) and E2k (-76%) declined, whereas E3 concentrations were unchanged. The results suggest that mitochondrial dysfunction is a part of the pathophysiological process in AD even when the primary pathogenic cause is nonmitochondrial.
CITATION STYLE
Gibson, G. E., Zhang, H., Sheu, K. F. R., Bogdanovich, N., Lindsay, J. G., Lannfelt, L., … Cowburn, R. F. (1998). α-ketoglutarate dehydrogenase in Alzheimer brains bearing the APP670/671 mutation. Annals of Neurology, 44(4), 676–681. https://doi.org/10.1002/ana.410440414
Mendeley helps you to discover research relevant for your work.